Diabetes-induced alterations in renal medullary microcirculation and metabolism

Current Diabetes Reviews

Volumn 3, Issue 1, 2007, Pages 53-65

  Nordquist, Lina ^a   Palm, Fredrik ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Diabetes; Microcirculation; Oxygen metabolism; Oxygen tension; Reactive oxygen species; Renal function; Renal medulla

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; AMINOGUANIDINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; ARGININE; BETA CAROTENE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; IMIRESTAT; PENTOSE PHOSPHATE; PLACEBO; POLYOL; PROTEIN KINASE C; PYCNOGENOL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THIOCTIC ACID;

CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG TARGETING; ENERGY METABOLISM; ENZYME ACTIVATION; GLUCOSE TRANSPORT; HUMAN; HYPERGLYCEMIA; HYPOTHESIS; IN VIVO STUDY; KIDNEY FUNCTION; KIDNEY MEDULLA; KIDNEY METABOLISM; MICROCIRCULATION; MORBIDITY; MORTALITY; NONHUMAN; OXYGEN TENSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; HYPERGLYCEMIA; KIDNEY MEDULLA; METABOLIC NETWORKS AND PATHWAYS; MICROCIRCULATION; MODELS, BIOLOGICAL; NITRIC OXIDE; OXYGEN CONSUMPTION;

EID: 34247173482     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339907779802120     Document Type: Review

References (162)

1. Cohen J, Kamm D. Renal metabolism: Relation to renal function. In: Brenner B, Rector F, Eds. The Kidney. Philadelphia: W.B. Saunders; 1985; 144-248.
2. Thaysen JH, Lassen NA, Munck O. Sodium transport and oxygen consumption in the mammalian kidney. Nature 1961; 190: 919-21.
3. Klahr S, Hammarman M. Renal metabolism. In: Seldin DW, Giebisch G, Eds. The Kidney: Physiology and Pathophysiology. New York: Raven Press; 1985; 699-718.
4. Chou SY, Porush JG, Faubert PF. Renal medullary circulation: hormonal control. Kidney Int 1990; 37(1): 1-13.
5. Aukland K, Krog J. Renal oxygen tension. Nature 1960; 188: 671.
6. Levy MN, Imperial ES. Oxygen shunting in renal cortical and medullary capillaries. Am J Physiol 1961; 200(1): 159-162.
7. Leonhardt KO, Landes RR. Oxygen tension of the urine and renal structures. Preliminary report of clinical findings. N Engl J Med 1963; 269: 115-21.
8. Aukland K. Studies on intrarenal circulation with special reference to gas exchange. J Oslo City Hosp 1964; 14: 115-46.
9. Brezis M, Heyman SN, Dinour D, Epstein FH, Rosen S. Role of nitric oxide in renal medullary oxygenation. Studies in isolated and intact rat kidneys. J Clin Invest 1991; 88(2): 390-5.
10. Epstein FH. Oxygen and renal metabolism. Kidney Int 1997; 51(2): 381-5.
11. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329(14): 977-86.
12. Brezis M, Rosen S. Hypoxia of the renal medulla - its implication for disease. N Engl J Med 1995; 332(10): 647-655.
13. Gabbay KH, Merola LO, Field RA. Sorbitol pathway: presence in nerve and cord with substrate accumulation in diabetes. Science 1966; 151(707): 209-10.
14. Brolin SE, Berggren PO, Naeser P. Fluorometric determination of Aldose Reductase in small tissue samples. Anal Chim Acta 1988; 206: 357-361.
15. Terubayashi H, Sato S, Nishimura C, Kador PF, Kinoshita JH. Localization of aldose and aldehyde reductase in the kidney. Kidney Int 1989; 36(5): 843-51.
16. Srivastava SK, Ramana, KV, Chandra D, Srivastava S, Bhatnagar A. Regulation of aldose reductase and the polyol pathway activity by nitric oxide. Chem Biol Interact 2003; 143-144: 333-40.
17. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54(6): 1615-25.
18. Williamson JR, Chang K, Frangos M, et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993; 42(6): 801-13.
19. Shah VO, Dorin RI, Sun Y, Braun M, Zager PG. Aldose reductase gene expression is increased in diabetic nephropathy. J Clin Endocrinol Metab 1997; 82(7): 2294-8.
20. Pugliese G, Tilton RG, Williamson JR. Glucose-induced metabolic imbalances in the pathogenesis of diabetic vascular disease. Diabetes Metab Rev 1991; 7(1): 35-59.
21. Stevens MJ, Dananberg J, Feldman EL, et al. The linked roles of nitric oxide, aldose reductase and, (Na+,K+)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest 1994; 94(2): 853-859.
22. Van den Enden MK, Nyengaard JR, Ostrow E, Burgan JH. Williamson JR, Elevated glucose levels increase retinal glycolysis and sorbitol pathway metabolism. Implications for diabetic retinopathy. Invest Ophthalmol Vis Sci 1995; 36(8): 1675-85.
23. Palm F, Hansell P, Ronquist G, Waldenstrom A, Liss P, Carlsson PO. Polyol-pathway-dependent disturbances in renal medullary metabolism in experimental insulin-deficient diabetes mellitus in rats. Diabetologia 2004; 47(7): 1223-1231.
24. Tilton RG, Baier LD, Harlow JE, Smith SR, Ostrow E, Williamson JR. Diabetes-induced glomerular dysfunction: links to a more reduced cytosolic ratio of NADH/NAD+. Kidney Int 1992; 41(4): 778-788.
25. Dorin RI, Shah VO, Kaplan DL, Vela BS, Zager PG. Regulation of aldose reductase gene expression in renal cortex and medulla of rats. Diabetologia 1995; 38(1): 46-54.
26. Kolm-Litty V, Sauer U, Nerlich A, Lehmann R, Schleicher ED. High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J Clin Invest 1998; 101(1): 160-9.
27. Weigert C, Friess U, Brodbeck K, Haring HU, Schleicher ED. Glutamine:fructose-6-phosphate aminotransferase enzyme activity is necessary for the induction of TGF-beta1 and fibronectin expression in mesangial cells. Diabetologia 2003; 46(6): 852-5.
28. Zhang H, Jia Y, Cooper JJ, Hale T, Zhang Z, Elbein SC. Common variants in glutamine:fructose-6-phosphate amidotransferase 2 (GFPT2) gene are associated with type 2 diabetes, diabetic nephropathy, and increased GFPT2 mRNA levels. J Clin Endocrinol Metab 2004; 89(2): 748-55.
29. Schleicher ED, Weigert C. Role of the hexosamine biosynthetic pathway in diabetic nephropathy. Kidney Int Suppl 2000; 77: S13-8.
30. Du XL, Edelstein D, Rossetti L, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A 2000; 97(22): 12222-6.
31. Ziyadeh FN, Sharma K, Ericksen M, Wolf G. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest 1994; 93(2): 536-42.
32. Daniels MC, McClain DA, Crook ED. Transcriptional regulation of transforming growth factor beta1 by glucose: investigation into the role of the hexosamine biosynthesis pathway. Am J Med Sci 2000; 319(3): 138-42.
33. Wang J, Liu R, Hawkins M, Barzilai N, Rossetti L. A nutrient-sensing pathway regulates leptin gene expression in muscle and fat. Nature 1998; 393(6686): 684-8.
34. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47(6): 859-66.
35. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996; 272(5262): 728-31.
36. Craven PA, Studer RK, DeRubertis FR. Impaired nitric oxide-dependent cyclic guanosine monophosphate generation in glomeruli from diabetic rats. Evidence for protein kinase C-mediated suppression of the cholinergic response. J Clin Invest 1994; 93(1): 311-20.
37. Craven PA, Studer RK, Felder J, Phillips S, DeRubertis FR. Nitric oxide inhibition of transforming growth factor-beta and collagen synthesis in mesangial cells. Diabetes 1997; 46(4): 671-81.
38. Kikkawa R, Koya D, Haneda M. Progression of diabetic nephropathy. Am J Kidney Dis 2003; 41(3 Suppl 1): S19-21.
39. Haneda M, Koya D, Kikkawa R. Cellular mechanisms in the development and progression of diabetic nephropathy: activation of the DAG-PKC-ERK pathway. Am J Kidney Dis 2001; 38(4 Suppl 1): S178-81.
40. Gagnon F, Hamet P, Orlov SN. Na+,K+ pump and Na+-coupled ion carriers in isolated mamalian kidney epithelial cells: regulation by protein kinase C. Can J Physiol Pharmacol 1999; 77(5): 305-19.
41. Craven PA, Studer RK, Negrete H, DeRubertis FR. Protein kinase C in diabetic nephropathy. J Diabetes Complications 1995; 9(4): 241-5.
42. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404(6779): 787-90.
43. Gerbitz KD, Gempel K, Brdiczka D. Mitochondria and diabetes. Genetic, biochemical, and clinical implications of the cellular energy circuit. Diabetes 1996; 45(2): 113-26.
44. Peragon J, Aranda F, Garcia-Salguero L, Vargas AM, Lupianez JA. Long-term adaptive response to dietary protein of hexose monophosphate shunt dehydrogenases in rat kidney tubules. Cell Biochem Funct 1990; 8(1): 11-7.
45. Peragon J, Aranda F, Garcia-Salguero L, Corpas FJ, Lupianez JA. Stimulation of rat-kidney hexose monophosphate shunt dehydrogenase activity by chronic metabolic acidosis. Biochem Int 1989; 18(5): 1041-50.
46. Peragon J, Aranda F, Garcia-Salguero L, Lupianez JA. Influence of experimental diabetes on the kinetic behaviour of renal cortex hexose monophosphate dehydrogenases. Int J Biochem 1989; 21(6): 689-94.
47. Steer KA, Sochor M, McLean P. Renal hypertrophy in experimental diabetes. Changes in pentose phosphate pathway activity. Diabetes 1985; 34(5): 485-90.
48. Tilton RG, Baier LD, Harlow JE, Smith SR, Ostrow E, Williamson JR. Diabetes-induced glomerular dysfunction: links to a more reduced cytosolic ratio of NADH/NAD+. Kidney Int 1992; 41(4): 778-88.
49. Grunewald RW, Weber, II, Kinne-Saffran E, Kinne RK. Control of sorbitol metabolism in renal inner medulla of diabetic rats: regulation by substrate, cosubstrate and products of the aldose reductase reaction. Biochim Biophys Acta 1993; 1225(1): 39-47.
50. Suresh Babu P, Srinivasan K. Amelioration of renal lesions associated with diabetes by dietary curcumin in streptozotocin diabetic rats. Mol Cell Biochem 1998; 181(1-2): 87-96.
51. Horie K, Miyata T, Maeda K, et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 1997; 100(12): 2995-3004.
52. Brownlee M, Vlassara H, Cerami A. Measurement of glycosylated amino acids and peptides from urine of diabetic patients using affinity chromatography. Diabetes 1980; 29(12): 1044-7.
53. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 1992; 15(12): 1835-43.
54. Brownlee M. The pathological implications of protein glycation. Clin Invest Med 1995; 18(4): 275-81.
55. Rosca MG, Mustata TG, Kinter MT, et al. Glycation of mitochondrial proteins from diabetic rat kidney is associated with excess superoxide formation. Am J Physiol Renal Physiol 2005; 289(2): F420-30.
56. Vlassara H, Brownlee M, Cerami A. Assessment of diabetic control by measurement of urinary glycopeptides. Diabetologia 1982; 23(3): 252-4.
57. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachectin/ TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 1988; 240(4858): 1546-8.
58. Nakamura S, Makita Z, Ishikawa S, et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 1997; 46(5): 895-9.
59. Abdel-Rahman E, Bolton WK. Pimagedine: a novel therapy for diabetic nephropathy. Expert Opin Investig Drugs 2002; 11(4): 565-74.
60. Bolton WK, Cattran DC, Williams ME, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004; 24(1): 32-40.
61. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40(4): 405-12.
62. Giugliano D, Ceriello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19(3): 257-67.
63. Koya D, Hayashi K, Kitada M, Kashiwagi A, Kikkawa R, Haneda M. Effects of antioxidants in diabetes-induced oxidative stress in the glomeruli of diabetic rats. J Am Soc Nephrol 2003; 14(8 Suppl 3): S250-3.
64. Zou AP, Cowley AW, Jr. Reactive oxygen species and molecular regulation of renal oxygenation. Acta Physiol Scand 2003; 179(3): 233-41.
65. Nagamatsu M, Nickander KK, Schmelzer JD, et al. Lipoic acid improves nerve blood flow, reduces oxidative stress, and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995; 18(8): 1160-7.
66. Packer L, Witt EH, Tritschler HJ. alpha-Lipoic acid as a biological antioxidant. Free Radic Biol Med 1995; 19(2): 227-50.
67. Chabrashvili T, Tojo A, Onozato ML, et al. Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension 2002; 39(2): 269-74.
68. Babior BM. NADPH oxidase. Curr Opin Immunol 2004; 16(1): 42-7.
69. Asaba K, Tojo A, Onozato ML, et al. Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int 2005; 67(5): 1890-8.
70. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86(5): 494-501.
71. Shiose A, Kuroda J, Tsuruya K, et al. A novel superoxide-producing NAD(P)H oxidase in kidney. J Biol Chem 2001; 276(2): 1417-23.
72. Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 2002; 61(1): 186-94.
73. Modlinger PS, Wilcox CS, Aslam S. Nitric oxide, oxidative stress, and progression of chronic renal failure. Semin Nephrol 2004; 24(4): 354-65.
74. Doi K, Noiri E, Tokunaga K. The association of NAD(P)H oxidase p22phox with diabetic nephropathy is still uncertain: response to Hodgkinson, Millward, and Demaine. Diabetes Care 2004; 27(6): 1518-9; author reply 1519.
75. Wolf G, Panzer U, Harendza S, Wenzel U, Stahl RA. No association between a genetic variant of the p22(phox) component of NAD(P)H oxidase and the incidence and progression of IgA nephropathy. Nephrol Dial Transplant 2002; 17(8): 1509-12.
76. Lim CS, Vaziri ND. Iron and oxidative stress in renal insufficiency. Am J Nephrol 2004; 24(6): 569-75.
77. Vaziri ND, Dicus M, Ho ND, Boroujerdi-Rad L, Sindhu RK. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int 2003; 63(1): 179-85.
78. Haque MZ, Majid DS. Assessment of renal functional. phenotype in mice lacking gp91PHOX subunit of NAD(P)H oxidase. Hypertension 2004; 43(2): 335-40.
79. Chabrashvili T, Kitiyakara C, Blau J, et al. Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol 2003; 285(1): R117-24.
80. Siu B, Saha J, Smoyer WE, Sullivan KA, Brosius FC, 3rd. Reduction in podocyte density as a pathologic feature in early diabetic nephropathy in rodents: prevention by lipoic acid treatment BMC Nephrol 2006; 7(1): 6.
81. Bhatti F, Mankhey RW, Asico L, Quinn MT, Welch WJ, Maric C. Mechanisms of antioxidant and pro-oxidant effects of alpha-lipoic acid in the diabetic and nondiabetic kidney. Kidney Int 2005; 67(4):1371-80.
82. Kitiyakara C, Chabrashvili T, Chen Y, et al. Salt intake, oxidative stress, and renal expression of NADPH oxidase and superoxide dismutase. J Am Soc Nephrol 2003; 14(11): 2775-82.
83. Prabhakar SS. Inhibition of mesangial iNOS by reduced extracellular pH is associated with uncoupling of NADPH oxidation. Kidney Int 2002; 61(6): 2015-24.
84. Tretter L, Adam-Vizi V. Generation of reactive oxygen species in the reaction catalyzed by alpha-ketoglutarate debydrogenase. J Neurosci 2004; 24(36): 7771-8.
85. Palm F, Cederberg J, Hansell P, Liss P, Carlsson PO. Reactive oxygen species cause diabetes-induced decrease in renal oxygen tension. Diabetologia 2003; 46(8): 1153-1160.
86. Berryman AM, Maritim AC, Sanders RA, Watkins JB, 3rd. Influence of treatment of diabetic rats with combinations of pycnogenol, beta-carotene, and alpha-lipoic acid on parameters of oxidative stress. J Biochem Mol Toxicol 2004; 18(6): 345-52.
87. Bach FH. Heme oxygenase-1 as a protective gene. Wien Klin Wochenschr 2002; 114 Suppl 4:1-3.
88. Maritim A, Dene BA, Sanders RA, Watkin JB, 3rd. Effects of pycnogenol treatment on oxidative stress in streptozotocin-induced diabetic rats. J Biochem Mol Toxicol 2003; 17(3): 193-9.
89. Korner A, Eklof AC, Celsi G, Aperia A. Increased renal metabolism in diabetes. Mechanism and functional implications. Diabetes 1994; 43(5): 629-33.
90. Palm F, Liss P, Fasching A, Hansell P, Carlsson PO. Transient glomerular hyperfiltration in the streptozotocin-diabetic Wistar Furth rat. Ups J Med Sci 2001; 106(3): 175-182.
91. Mogensea CE. Glomerular filtration rate and renal plasma flow in normal and diabetic man during elevation of blood sugar levels. Scand J Clin Lab Invest 1971; 28(2): 177-82.
92. Koivisto A, Matthias A, Bronnikov G, Nedergaard J. Kinetics of the inhibition of mitochondrial respiration by NO. FEBS Lett 1997; 417(1): 75-80.
93. Schnackenberg CG. Physiological and pathophysiological roles of oxygen radicals in the renal microvasculature. Am J Physiol Regul Integr Comp Physiol 2002; 282(2): R335-R342.
94. Peroni O, Large V, Diraison F, Beylot M. Glucose production and gluconeogenesis in postabsorptive and starved normal and streptozotocin-diabetic rats. Metabolism 1997; 46(11): 1358-63.
95. Guder WG, Schmolke M, Wirthensohn G. Carbohydrate and lipid metabolism of the renal tubule in diabetes mellitus. Eur J Clin Chem Clin Biochem, 1992; 30(10): 669-74.
96. Thorens B. Glucose transporters in the regulation of intestinal, renal, and liver glucose fluxes. Am J Physiol 1996; 270(4 Pt 1): G541-53.
97. Morrissey JJ, McCracken R, Kaneto H, Vehaskari M, Montani D, Klahr S. Location of an inducible nitric oxide synthase mRNA in the normal kidney. Kidney Int 1994; 45(4): 998-1005.
98. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43(2): 109-42.
99. Ghasfourifar P, Cadenas; E. Mitochondrial nitric oxide synthase. Trends Pharmacol Sci 2005; 26(4): 190-5.
100. Palm F, Buerk DG, Carlsson PO, Hansell P, Liss P. Reduced nitric oxide concentration in the renal cortex of streptozotocin-induced diabetic rats: effects on renal oxygenation and microcirculation. Diabetes 2005; 54(11): 3282-7.
101. Mumtaz FH, Dashwood MR, Khan MA, Thompson CS, Mikhailidis DP, Morgan RJ. Down-regulation of nitric oxide synthase in the diabetic rabbit kidney: potential relevance to the early pathogenesis of diabetic nephropathy. Curr Med Res Opin 2004; 20(1): 1-6.
102. Khamaisi M, Keynan S, Bursztyn M, et al. Role of Renal Nitric Oxide Synthase in Diabetic Kidney Disease during the Chronic Phase of Diabetes. Nephron Physiol 2005; 102(3-4): pp. 72-p80.
103. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational. modification at the Akt site. J Clin Invest 2001; 108(9): 1341-8.
104. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339(8793): 572-5.
105. Tojo A, Welch WJ, Bremer V, et al. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int 1997; 52(6): 1593-601.
106. Kielstein JT, Boger RH, Bode-Boger SM, et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002; 13(1): 170-6.
107. Tamow L, Hovind P, Teerlink T, Stehouwer CD, Parving HH. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephopathy in type 1 diabetes. Diabetes Care 2004; 27(3): 765-9.
108. Zoccali C, Bode-Roger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358(9299): 2113-7.
109. Yang ZZ, Zhang AY, Yi FX, Li PL, Zou AP. Redox regulation of HIF-1alpha levels and HO-1 expression in renal medullary interstitial cells. Am J Physiol Renal Physiol 2003; 284(6): F1207-15.
110. Brezis M, Agmon Y, Epstein FH. Determinants of intrarenal oxygenation. I. Effects of diuretics. Am J Physiol 1994; 267(6 Pt 2): F1059-62.
111. Siragy HM, Ibrahim MM, Jaffa AA, Mayfield R, Margolius HS. Rat renal interstitial bradykinin, prostaglandin E2, and cyclic guanosine 3′,5′-monophosphate. Effects of altered sodium intake. Hypertension 1994; 23(6 Pt 2): 1068-70.
112. Roman RJ, Zou AP. Influence of the renal medullary circulation on the control of sodium excretion. Am J Physiol 1993; 265(5 Pt 2): R963-73.
113. Craven PA, DeRubertis FR. Calcium and prostaglandin E2 in renomedullary interstitial cells. Hypertension 1991; 17(3): 303-7.
114. DeRubertis FR, Craven PA. Eicosanoids in the pathogenesis of the functional and structural alterations of the kidney in diabetes. Am J Kidney Dis 1993; 22(5): 727-35.
115. Benigni A, Colosio V, Brena C, Bruzzi I, Bertani T, Remuzzi G. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes 1998; 47(3): 450-6.
116. Khan MA, Dashwood MR, Mumtaz FH, Thompson CS, Mikhailidis DP, Morgan RJ. Upregulation of endothelin A receptor sites in the rabbit diabetic kidney: potential relevance to the early pathogenesis of diabetic nephropathy. Nephron 1999; 83(3): 261-7.
117. Prabhakar SS. Regulatory and functional interaction of vasoactive factors in the kidney and extracellular pH. Kidney Int 2004; 66(5): 1742-54.
118. Bierhaus A, Chevion S, Chevion M, et al. Advanced glycation end product-induced activation of NF-kappaB is suppressed by alphalipoic acid in cultured endothelial cells. Diabetes 1997; 46(9): 1481-90.
119. Michael JR, Markowitz BA, Kohan DE. Oxidant stress regulates basal endothelin-1 production by cultured rat pulmonary endothelial cells. Am J Physiol 1997; 273(4 Pt 1): L768-74.
120. Hughes AK, Stricklett PK, Padilla E, Kohan DE. Effect of reactive oxygen species on endothelin-1 production by human mesangial cells. Kidney Int 1996; 49(1): 181-9.
121. Love GP, Keenan AK. Cytotoxicity-associated effects of reactive oxygen species on endothelin-1 secretion by pulmonary endothelial cells. Free Radic Biol Med 1998; 24(9): 1437-45.
122. Kohan DE. Endothelins in the normal and diseased kidney. Am J Kidney Dis 1997; 29(1): 2-26.
123. Erley CM, Duda SH, Schlepckow S, et al. Adenosine antagonist theophylline prevents the reduction of glomerular filtration rate after contrast media application. Kidney Int 1994; 45(5): 1425-31.
124. Pflueger A, Larson TS, Nath KA, King BF, Gross JM, Knox FG. Role of adenosine in contrast media-induced acute renal failure in diabetes mellitus. Mayo Clin Proc 2000; 75(12): 1275-83.
125. Pawelczyk T, Grden M, Rzepko R, Sakowicz M, Szutowicz A. Region-specific alterations of adenosine receptors expression level in kidney of diabetic rat. Am J Pathol 2005; 167(2): 315-25.
126. Awad AS, Huang L, Ye H, et al. Adenosine 2A Receptor Activation Attenuates Inflammation and Injury in Diabetic Nephropathy. Am J Physiol Renal Physiol. 2006; 290(4): F828-37.
127. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000; 342(6): 381-9.
128. Nicholls K. Diabetic nephropathy - how might we prevent, retard, or cope with it? Aust Fam Physician 2005; 34(11):933-6.
129. Thorp ML. Diabetic nephropathy: common questions. Am Fam Physician 2005; 72(1):96-9.
130. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118(2): 129-38.
131. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of Iosartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345(12): 861-9.
132. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345(12): 870-8.
133. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345(12): 851-60.
134. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. ACE Inhibitors in Diabetic Nephropathy Trialist Group. Ann Intern Med 2001; 134(5):370-9.
135. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998; 128(12 Pt 1): 982-8.
136. Raij L, Shultz PJ, Tolins JP. Possible mechanism for the renoprotective effect of angiotensin converting enzyme inhibitors. J Hypertens Suppl 1989; 7(7): S33-6; discussion S36-7.
137. Fabris B, Candido R, Carraro M, et al. Modulation of incipient glomerular lesions in experimental diabetic nephropathy by hypotensive and subhypotensive dosages of an ACE inhibitor. Diabetes 2001; 50(11): 2619-24.
138. Frohlich ED. Angiotensin converting enzyme inhibitors. Present and future. Hypertension 1989; 13(5 Suppl): I125-30.
139. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005; 366(9502):2026-33.
140. Touyz RM, Yao G, Viel E, Amiri F, Schiffrin EL. Angiotensin II and endothelin-1 regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells. J Hypertens 2004; 22(6): 1141-9.
141. Wilcox CS. Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? Am J Physiol Regul Integr Comp Physiol 2005; 289(4): R913-35.
142. Cifuentes ME, Rey FE, Carretero OA, Pagano PJ. Upregulation of p67(phox) and gp91(phox) in aortas from angiotensin II-infused mice. Am J Physiol Heart Circ Physiol 2000; 279(5): H2234-40.
143. Rey FE, Cifuentes ME, Kiarash A, Quinn MT, Pagano PJ. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ Res 2001; 89(5): 408-14.
144. Landmesser U, Cai H, Dikalov S, et al. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 2002; 40(4): 511-5.
145. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351(19): 1952-61.
146. Sengul AM, Altuntas Y, Kurklu A, Aydin L. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. Diabetes Res Clin Pract 2006; 71(2): 210-9.
147. Krimholtz MJ, Karalliedde J, Thomas S, Bilous R, Viberti G. Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease. J Am Soc Nephrol 2005; 16 Suppl 1: S42-7.
148. Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998; 54(3): 889-96.
149. Locatelli F, Pozzoni P, Del Vecchio L. Renal replacement therapy in patients with diabetes and end-stage renal disease. J Am Soc Nephrol 2004; 15 Suppl 1: S25-9.
150. Schomig M, Ritz E. Cardiovascular problems in diabetic patients on renal replacement therapy. Nephrol Dial Transplant 2000; 15 Suppl 5: 111-6.
151. Engerman RL, Kern TS, Larson ME. Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs. Diabetologia 1994; 37(2): 141-4.
152. Kern TS, Engerman RL. Aldose reductase and the development of renal disease in diabetic dogs. J Diabetes Complications 1999; 13(1): 10-6.
153. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986; 232(4758): 1629-32.
154. Suganami T, Mukoyama, M, Mori K, et al. Prevention and reversal of renal injury by leptin in a new mouse model of diabetic nephropathy. FASEB J 2005; 19(1): 127-9.
155. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339(2): 69-75.
156. Wahren J. C-peptide: new findings and therapeutic implications in diabetes. Clin Physiol Funct Imaging 2004; 24(4): 180-9.
157. Wahren J, Shafqat J, Johansson J, Chibalin A, Ekberg K, Jornvall H. Molecular and cellular effects of C-peptide-new perspectives on an old peptide. Exp Diabesity Res 2004; 5(1): 15-23.
158. Sato Y, Oshida Y, Han YQ, et al. C-peptide fragments stimulate glucose utilization in diabetic rats. Cell Mol Life Sci 2004; 61(6): 727-32.
159. Tsimaratos M. [Physiological effects of C-peptide]. Nephrologie 2004; 25(5): 155-61.
160. Sima AA. Diabetic neuropathy in type 1 and type 2 diabetes and the effects of C-peptide. J Neurol Sci 2004; 220(1-2): 133-6.
161. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003; 348(23): 2285-93.
162. Palm F, Ortsäter H, Hansell P, Liss P, Carlsson PO. Differentiating between effects of streptozotocin per se and subsequent hyperglycemia on renal function and metabolism in the streptozotocin-diabetic rat model. Diabetes Metab Res Rev 2004; 20(6): 452-459.